Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calistoga Pharmaceuticals has initiated a Phase I clinical trial of its lead compound, CAL-101, a small molecule phosphoinositide-3 kinase delta inhibitor, in patients with hematologic cancer.
Subscribe to our email newsletter
This open label trial will explore the safety and clinical activity of CAL-101 in patients with chronic lymphocytic leukemia, selected B-cell non-Hodgkin lymphoma and acute myeloid leukemia.
Albert Yu, vice president of clinical affairs and chief medical officer of Calistoga, said: “We at Calistoga are very pleased to be entering our first oncology trial. PI3K delta is a novel target in cancer, and we look forward to evaluating CAL-101 as a potential treatment to improve outcomes in patients with certain types of leukemias and lymphomas.”